Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use
…
Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.
Covered entities reported receiving letters from Bayer about
…
Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.
The U.S. Health Resources and Services
…
Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.
Consultants and attorneys with
…
The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer
…
The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar bottom lines.”
…
Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.
If the court disagrees,
…
UPDATE Friday, March 31, 2023, 6:45 p.m. EDT—Story updated with comment from the National Association of Community Health Centers.
Drug manufacturer GlaxoSmithKline this afternoon announced a major expansion of its conditions on 340B pricing in the contract
…
Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.
Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer
…*Sign up for news summaries and alerts from 340B Report